Catalent, Inc. (NYSE:CTLT) Receives Average Rating of “Hold” from Analysts

Catalent, Inc. (NYSE:CTLT) has been assigned an average rating of “Hold” from the eight ratings firms that are currently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $59.83.

CTLT has been the subject of several research analyst reports. William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Robert W. Baird restated a “neutral” rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. Finally, StockNews.com upgraded shares of Catalent from a “sell” rating to a “hold” rating in a report on Thursday.

Insider Buying and Selling

In related news, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.31% of the stock is owned by company insiders.

Institutional Trading of Catalent

Hedge funds have recently made changes to their positions in the company. Gamco Investors INC. ET AL lifted its stake in shares of Catalent by 403.3% in the 1st quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company’s stock worth $1,428,000 after acquiring an additional 20,273 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Catalent by 2,792.9% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock worth $29,150,000 after acquiring an additional 498,540 shares during the period. UniSuper Management Pty Ltd lifted its stake in shares of Catalent by 509.4% in the 1st quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company’s stock worth $1,028,000 after acquiring an additional 15,217 shares during the period. Swedbank AB acquired a new stake in shares of Catalent in the 1st quarter worth $1,659,000. Finally, SG Americas Securities LLC lifted its stake in shares of Catalent by 147.4% in the 1st quarter. SG Americas Securities LLC now owns 99,588 shares of the company’s stock worth $5,622,000 after acquiring an additional 59,339 shares during the period.

Catalent Trading Down 0.2 %

Shares of NYSE:CTLT opened at $59.15 on Thursday. Catalent has a 52 week low of $34.92 and a 52 week high of $61.20. The company’s 50 day moving average is $59.89 and its two-hundred day moving average is $58.16. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The company has a market cap of $10.74 billion, a PE ratio of -26.17, a P/E/G ratio of 2.36 and a beta of 1.16.

Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the previous year, the company posted ($0.10) EPS. The company’s quarterly revenue was up 4.2% on a year-over-year basis. Equities analysts predict that Catalent will post 0.84 earnings per share for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.